Segment Information

Segment reporting is prepared on the same basis that the Company’s chief executive officer, who is the Company’s chief operating decision maker, manages the business, makes operating decisions and assesses performance. The Company operates in one segment, pharmaceuticals. Enterprise-wide disclosures about revenues, significant customers, and property and equipment, net by location are presented below.

Revenues by Product

Product revenues, net consisted of the following:



	2018 (as reported under ASC 606)		2017 (as reported under ASC 605)		2016 (as reported under ASC 605)
	(in thousands)
SYMDEKO/SYMKEVI	$	768,657	$	—	$	—
ORKAMBI	1,262,166		1,320,850		979,590
KALYDECO	1,007,502		844,630		703,432
Other	—		—		610
Total product revenues, net	$	3,038,325	$	2,165,480	$	1,683,632

Revenues by Geographic Location

Net product revenues are attributed to countries based on the location of the customer. Collaborative and royalty revenues are attributed to countries based on the location of the Company’s subsidiary associated with the collaborative arrangement related to such revenues. Total revenues from external customers and collaborators by geographic region consisted of the following:



	2018 (as reported under ASC 606)		2017 (as reported under ASC 605)		2016 (as reported under ASC 605)
	(in thousands)
United States	$	2,365,079	$	1,986,786	$	1,321,807
Outside of the United States
Europe	543,179		420,317		320,456
Other	139,339		81,549		59,914
Total revenues outside of the United States	682,518		501,866		380,370
Total revenues	$	3,047,597	$	2,488,652	$	1,702,177

In 2018, 2017 and 2016, revenues attributable to Germany and the United Kingdom contributed the largest amounts to the Company’s European revenues.

Significant Customers

Gross revenues and accounts receivable from each of the Company’s customers who individually accounted for 10% or more of total gross revenues and/or 10% or more of total gross accounts receivable consisted of the following:



	Percent of Total Gross Revenues						Percent of Gross Accounts Receivable
	Year Ended December 31,						As of December 31,
	2018 (as reported under ASC 606)		2017 (as reported under ASC 605)		2016 (as reported under ASC 605)		2018		2017
Walgreen Co.	20	%	17	%	19	%	16	%	20	%
Accredo/Curascript	14	%	14	%	15	%	10	%	12	%
McKesson Corporation	14	%	<10	%	<10	%	16	%	<10	%
CVS/Caremark	n/a		<10	%	19	%	n/a		n/a

Property and Equipment, Net by Location

Property and equipment, net by location consisted of the following:



	As of December 31,
	2018		2017
	(in thousands)
United States	$	778,157	$	753,128
Outside of the United States
United Kingdom	30,496		31,279
Other	3,352		5,030
Total property and equipment, net outside of the United States	33,848		36,309
Total property and equipment, net	$	812,005	$	789,437